Secondary Logo

Institutional members access full text with Ovid®

Share this article on:

Fluorescein Aqueous Angiography in Live Normal Human Eyes

Huang, Alex S., MD, PhD*; Penteado, Rafaella C., MD; Saha, Sajib K., PhD*; Do, Jiun L., MD, PhD; Ngai, Philip, MD, MBA; Hu, Zhihong, PhD*; Weinreb, Robert N., MD

doi: 10.1097/IJG.0000000000001042
Original Studies

Purpose: To evaluate aqueous humor outflow (AHO) in intact eyes of live human subjects during cataract surgery using fluorescein aqueous angiography.

Methods: Aqueous angiography was performed in 8 live human subjects (56 to 86 y old; 2 men and 6 women). After anesthesia, fluorescein (2%) was introduced into the eye [either alone or after indocyanine green (ICG; 0.4%)] from a sterile, gravity-driven constant-pressure reservoir. Aqueous angiographic images were obtained with a Spectralis HRA+OCT and FLEX module (Heidelberg Engineering). Using the same device, anterior-segment optical coherence tomography (OCT) and infrared images were also concurrently taken with aqueous angiography.

Results: Fluorescein aqueous angiography in the live human eye showed segmental AHO patterns. Initial angiographic signal was seen on average by 14.0±3.0 seconds (mean±SE). Using multimodal imaging, angiographically positive signal colocalized with episcleral veins (infrared imaging) and intrascleral lumens (anterior-segment OCT). Sequential aqueous angiography with ICG followed by fluorescein showed similar segmental angiographic patterns.

Discussion: Fluorescein aqueous angiography in live humans was similar to that reported in nonhuman primates and to ICG aqueous angiography in live humans. As segmental patterns with sequential angiography using ICG followed by fluorescein were similar, these tracers can now be used sequentially, before and after trabecular outflow interventions, to assess their effects on AHO in live human subjects.

*Department of Ophthalmology, Doheny Eye Institute, David Geffen School of Medicine at UCLA, Los Angeles

Department of Ophthalmology, Hamilton Glaucoma Center, Shiley Eye Institute, University of California, San Diego, CA

Supported by National Institutes of Health, Bethesda, MD (grant numbers K08EY024674 (A.S.H.). Heidelberg Engineering (research support); Glaukos Corporation (research support); Diagnosys LLC (research support); Aerie Pharmaceuticals (Consultant) (A.S.H.) and R01EY029058 (R.N.W.); Research to Prevent Blindness Career Development Award 2016 (A.S.H.); and an unrestricted grant from Research to Prevent Blindness (UCLA and UCSD) (New York, NY).

Disclosure: The authors declare no conflict of interest.

Reprints: Alex S. Huang, MD, PhD, Department of Ophthalmology, Doheny Eye Institute, David Geffen School of Medicine, University of California, 1355 San Pablo Street, Los Angeles, CA 90033 (e-mail: ahuang@doheny.org).

Received April 23, 2018

Accepted July 28, 2018

Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.